Tonix Pharmaceuticals Holding Corp. Q3 2026 Earnings Call Summary Moby Intelligence Mon, November 9, 2026 at 5:13 PM EST 3 min read NVDA -4.09% TNXP +0.21% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
TONMYA's 37% quarter-over-quarter growth was primarily driven by the pull-through of commercial payer agreements and more favorable gross-to-net adjustments than initially anticipated.
The September 1 expansion to 150 sales representatives significantly increased prescriber reach and field activity, resulting in meaningful growth in new prescriptions and refills.
Management attributes the decline in bridge prescriptions to successful market access efforts, with approximately 53% of U.S. covered lives now having insurance access to TONMYA.
Strategic marketing initiatives, including a doubling of unaided brand awareness since February, are focused on educating providers that fibromyalgia is a distinct, diagnosable condition rather than a diagnosis of exclusion.
The company is vigorously defending its intellectual property against a Paragraph IV patent certification from Dr. Reddy's, asserting that its core patents provide protection through 2034.
Operational focus has shifted toward high-value clinical programs, including the Phase II HORIZON study for major depressive disorder and the TRAIL study for Lyme disease prevention.
The Phase II TRAIL study for Lyme disease prevention is scheduled to initiate in Q1 2027, utilizing an adaptive design to evaluate safety in a 500-participant lead-in cohort.
Management expects the current cash position, bolstered by post-quarter equity proceeds, to fund operations and capital expenditures into the early third quarter of 2027.
Future TONMYA growth is expected to be driven by deepening prescriber relationships and expanding coverage through ongoing negotiations with managed Medicare and commercial payers.
The Phase II investigator-initiated study of TNX-1500 for kidney transplant rejection is slated to begin in Q1 2027, aiming to demonstrate safety with reduced conventional immunosuppression.
Management anticipates that the full impact of the sales force expansion will be realized throughout 2027 as the team reaches approximately 70% of the target prescriber market.
Dr. Reddy's Laboratories filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, a common generic challenge that Tonix intends to litigate vigorously.
Research and development expenses increased to $25.8 million, reflecting higher manufacturing and clinical costs associated with advancing the prioritized pipeline.
Selling, general, and administrative expenses rose to $45.6 million, primarily due to a $13.5 million increase in sales and marketing costs for the TONMYA launch.
Management reports strong patient persistence and positive anecdotal feedback regarding efficacy and tolerability, with refills growing 56% in the third quarter.
Growth in 2027 is expected to stem from the full impact of the 150-person sales force and continued improvement in the bridge-to-paid script conversion rate.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
The 2027 lead-in cohort of 500 participants will focus on safety, while the company uses AI-driven epidemiology to optimize site selection for the 2028 efficacy phase.
Management expressed confidence in the study timeline following a favorable Type C meeting with the FDA regarding the randomized, placebo-controlled design.
Management observes a "sea change" in rheumatology, where fibromyalgia is increasingly recognized as a distinct condition requiring separate treatment even when concurrent with autoimmune diseases.
While TONMYA is studied as a monotherapy, its role is expanding as clinicians identify "concomitant fibromyalgia" in patients with rheumatoid arthritis and lupus.
The company is actively exploring out-licensing and partnerships for non-core assets to extend its runway beyond the current Q3 2027 guidance.
Management views the upcoming safety data from the Lyme disease program as a significant value-inflection point for potential partners.
Development is currently at an impasse as the company awaits FDA feedback on a proposed approval path based on laboratory studies rather than traditional clinical trials.
